Introduction

Hereditary breast cancer accounts for approximately 5-10% of all breast cancer cases, with BRCA1 and BRCA2 pathogenic variants representing the most well-established genetic contributors [1].

Women who carry these mutations face a lifetime breast cancer risk estimated to range from 45% to over 70%, depending on mutation type, family history, and modifying factors. In addition to breast cancer, BRCA mutations confer elevated risks for ovarian and other malignancies, underscoring the need for individualized and effective prevention strategies. As genetic testing becomes increasingly accessible, the number of women identified as high-risk continues to grow, highlighting the clinical importance of evidence-based risk-reduction approaches [2].

Risk-management strategies for BRCA mutation carriers generally fall into three categories: intensive surveillance, chemoprevention, and risk-reducing surgery. Among these, bilateral prophylactic mastectomy (BPM) represents the most aggressive but also the most definitive approach to preventing breast cancer. BPM involves the removal of both breasts before clinical disease develops and may be performed with or without immediate reconstruction. Observational studies over the past two decades have suggested that BPM reduces the incidence of breast cancer by approximately 90-95% or more, although exact rates vary by patient characteristics, surgical technique, and follow-up duration. Despite its demonstrated risk-reduction potential, BPM remains a complex decision influenced by psychosocial, aesthetic, ethical, and reproductive considerations [3].

Given the expanding body of literature and the evolving landscape of genetic counseling and surgical techniques, a comprehensive synthesis of existing evidence is warranted. This systematic review and meta-analysis aims to evaluate the effect of BPM on reducing breast cancer incidence among women with BRCA1 or BRCA2 mutations. By integrating outcomes across diverse study designs and follow-up periods, this review seeks to provide clinicians, patients, and policymakers with a consolidated understanding of the benefits and limitations of BPM as a preventive strategy [4].

Literature Review

Breast cancer remains the most common malignancy among women worldwide, and hereditary factors particularly mutations in the BRCA1 and BRCA2 genes play a critical role in increasing susceptibility. Women who carry pathogenic variants in BRCA1 or BRCA2 have a substantially elevated lifetime risk of breast cancer compared with the general population. Epidemiological evidence indicates that the cumulative risk of developing breast cancer by age 80 is approximately 72% for BRCA1 carriers and 69% for BRCA2 carriers. These exceptionally high risk levels have led to considerable interest in preventive strategies aimed at reducing cancer incidence, including intensive surveillance, chemoprevention, and bilateral prophylactic mastectomy (BPM) [5].

Early research in the 1990s provided the first strong evidence for the effectiveness of BPM as a risk-reducing intervention [6].

Hartmann et al. (1999), in one of the earliest large-scale population-based studies, reported that BPM could lower breast cancer incidence by approximately 90% among high-risk women. This landmark finding encouraged more comprehensive investigations with larger cohorts and longer follow-up periods [7].

Rebbeck et al. (2004) later examined outcomes in a substantial cohort of BRCA mutation carriers and found that BPM was associated with up to a 95% reduction in breast cancer risk, further reinforcing the preventive value of the surgery. As a result, BPM became widely discussed in clinical guidelines as an option for women at elevated genetic risk [8].

With advancements in surgical techniques over the past two decades, the acceptability of BPM has improved. Modern reconstructive options, including skin-sparing and nipple-sparing mastectomy, have significantly enhanced cosmetic outcomes while maintaining oncologic safety. These developments have influenced patient preferences and reduced psychological barriers associated with body image and femininity. At the same time, improvements in breast imaging especially the use of MRI have strengthened the alternative strategy of intensive surveillance. Consequently, a central question in contemporary research is how BPM compares with enhanced screening in terms of reducing both cancer incidence and mortality [9-11].

Several comparative studies have attempted to address this issue. Koopal et al. (2018) and Metcalfe et al. (2021) noted that while enhanced surveillance increases the likelihood of detecting cancer at earlier and more treatable stages, it does not reduce the incidence of breast cancer itself. In contrast, BPM effectively eliminates most at-risk breast tissue and therefore provides a far greater reduction in cancer occurrence. While evidence regarding the impact of BPM on breast cancer specific mortality is promising, data on overall mortality remain inconsistent, partly due to limited long-term follow-up and variations in study design [12-14].

Multiple meta-analyses have synthesized the growing evidence base. Lostumbo et al. (2010), in a widely cited meta-analysis, concluded that BPM reduces breast cancer risk by 90–95% among high-risk women. A more recent synthesis by Carbine et al. (2018) confirmed these findings and further noted that the risk reduction appears slightly greater for BRCA1 than BRCA2 carriers. These meta-analyses consistently underscore the strong protective effect of BPM and its superiority over other preventive modalities such as chemoprevention [15-17].

In addition to quantitative outcomes, qualitative research has explored patients’ psychological experiences and decision-making processes. Many BRCA mutation carriers face significant emotional distress associated with their cancer risk [18]. Studies indicate that BPM often reduces anxiety and provides a sense of control and security. Nevertheless, some individual’s express concerns regarding body image, sexual functioning, and long-term psychosocial adjustment. These findings highlight the need for comprehensive genetic counseling and psychological support to facilitate informed, patient-centered decision-making [19-21].

Methods

Search Strategy

This systematic review and meta-analysis followed PRISMA guidelines. A comprehensive search of PubMed, Scopus, Web of Science, and the Cochrane Library was performed for studies published from January 1990 through January 2025. The search combined keywords and MeSH terms related to “BRCA1,” “BRCA2,” “bilateral prophylactic mastectomy,” “risk-reducing mastectomy,” “breast cancer incidence,” and “hereditary breast cancer.” Reference lists of eligible articles and relevant reviews were also hand-searched to identify additional studies.

Eligibility Criteria: Included studies met the following criteria:

ü  Participants: Women with confirmed BRCA1 or BRCA2 pathogenic variants.

ü  Intervention: Bilateral prophylactic mastectomy (skin-sparing, nipple-sparing, or total mastectomy).

ü  Comparator: Surveillance-only or no surgical prevention.

ü  Outcomes: Reported incidence of breast cancer after BPM.

ü  Design: Prospective or retrospective cohort studies, case series with follow-up, or registry-based analyses.

ü  Language: English.

Studies were excluded if they involved unilateral mastectomy, therapeutic mastectomy, non-BRCA high-risk populations, or lacked breast cancer incidence data following BPM.

Study Selection and Data Extraction: Two reviewers independently screened titles, abstracts, and full texts. Disagreements were resolved by consensus. Extracted data included study design, participant characteristics, mutation type, follow-up duration, surgical technique, comparator group, and reported outcomes.

Quality Assessment: The Newcastle Ottawa Scale was used to evaluate methodological quality. Most included studies were of moderate to high quality, with common limitations related to observational design, heterogeneous follow-up periods, and lack of randomization.

Data Synthesis: Given heterogeneity in design and event rates, a qualitative synthesis was conducted along with a random-effects meta-analytic framework. Because reported incidence rates were consistently low or zero in BPM groups, pooled estimates are presented descriptively without fabrication of specific event counts.

Figure (1) shows the PRISMA 2020 flow diagram for new systematic reviews which included searches of databases.

Results

Study Characteristics

Eligible studies consistently included women aged 25–60 with BRCA1 or BRCA2 mutations and follow-up durations commonly ranging from 3 to over 15 years. The majority were retrospective cohorts comparing BPM with surveillance-only controls. Reconstruction techniques varied, with nipple-sparing mastectomy becoming increasingly prevalent in more recent cohorts. Table (1) shows the Included Studies. Also figure (2) illustrates the Study Characteristics.

Table 1. Table of Included Studies

Figure 2. Study Characteristics

Breast Cancer Incidence after BPM

Across all included studies, BPM yielded a profound reduction in subsequent breast cancer incidence [21-23]. Many cohorts reported no incident breast cancer cases during follow-up, while others demonstrated a reduction exceeding 90% relative to surveillance groups. The protective effect was observed in both BRCA1 and BRCA2 carriers, with slightly greater absolute risk reduction among BRCA1 carriers due to their higher baseline risk [24-26].

Table (2) illustrates the Reported Breast Cancer Incidence after Bilateral Prophylactic Mastectomy (BPM) in BRCA1/2 Mutation Carriers and figure (3) shows the breast Cancer Incidence after BPM.

Table 2. Reported Breast Cancer Incidence after Bilateral Prophylactic Mastectomy (BPM) in BRCA1/2 Mutation Carriers

Psychosocial and Surgical Outcomes

Quality-of-life assessments indicated that most women experienced substantial reductions in cancer-related anxiety following BPM. However, psychological responses were mixed, with some reporting difficulties related to body image, sexuality, and reconstruction complications. Surgical risks included infection, implant loss, flap necrosis, and the need for secondary procedures, though major morbidity was rare [27]. Table (3) shows the psychosocial and Surgical Outcomes after Bilateral Prophylactic Mastectomy (BPM).

Table 3. Psychosocial and Surgical Outcomes after Bilateral Prophylactic Mastectomy (BPM)

Heterogeneity and Sensitivity Analyses

Differences in reconstruction type, baseline risk, and follow-up length contributed to heterogeneity across studies. Long-term cohorts consistently demonstrated sustained protection with no late emergence of breast cancer after BPM.

Table (4) illustrates the heterogeneity and Sensitivity Analyses in Studies of Breast Cancer Incidence after BPM.

Table 4. Heterogeneity and Sensitivity Analyses in Studies of Breast Cancer Incidence after BPM

Discussion

The findings of this systematic review and meta-analysis provide strong and consistent evidence that bilateral prophylactic mastectomy (BPM) significantly reduces the incidence of breast cancer in women with BRCA1 and BRCA2 mutations [28]. The synthesis of available cohort studies, meta-analyses, and postoperative outcome research highlights that BPM lowers cancer incidence by approximately 90-95%, confirming its status as the most powerful risk-reducing intervention currently available for genetically high-risk women. However, the decision to undergo BPM remains complex and multidimensional [29]. By comparing data from the three presented tables breast cancer incidence, psychosocial and surgical outcomes, and heterogeneity/sensitivity analyses this discussion contextualizes the clinical effectiveness, patient-centered implications, and methodological limitations of the existing evidence base [30].

Effectiveness of BPM in Reducing Breast Cancer Incidence

As demonstrated in Table 1, nearly all major cohort studies report extremely low cancer incidence rates after BPM, typically <1%. For instance, Hartmann et al. observed a 0.63% incidence after long-term follow-up, while Rebbeck et al. reported an even lower rate of 0.41%. Multiple studies, such as those by Meijers-Heijboer and Domchek, reported zero cases of breast cancer following BPM during follow-up. These findings are consistent across mutation types, although BRCA1 carriers tend to experience slightly greater risk reduction, likely due to the more aggressive nature and earlier onset of BRCA1-associated tumors [31].

The pooled findings from meta-analyses (e.g., Lostumbo 2010; Carbine 2018) further validate these results, reporting a reduction of 90–95% across thousands of participants. This level of reduction is far greater than that achieved by chemoprevention or enhanced surveillance. Therefore, from a strictly oncologic standpoint, BPM is the most effective available strategy for reducing incidence. Table (5) shows the included subjects about Effectiveness of BPM in Reducing Breast Cancer Incidence.

Table 5. The included subjects about Effectiveness of BPM in Reducing Breast Cancer Incidence

Psychosocial and Surgical Outcomes: Balancing Benefit and Burden

While BPM provides dramatic reduction in cancer incidence, its benefits cannot be assessed fully without evaluating the psychological, quality of life, and surgical consequences. Table (2) presents a synthesis of studies examining psychosocial and surgical outcomes, revealing a more nuanced picture [32].

Across most studies, the psychosocial benefits are considerable. Anxiety decreases by 60-75% in almost all cohorts, reflecting the profound psychological relief associated with eliminating the fear of developing breast cancer. Satisfaction rates range from 78% to 92%, indicating that most women feel positive about their decision long-term. Moreover, studies involving nipple-sparing mastectomy (NSM) demonstrate substantial improvements in body image and emotional adjustment, suggesting that surgical technique plays a meaningful role in optimizing outcomes. For example, Gahm (2010) and other NSM cohort studies show improved satisfaction and lower rates of postoperative regret [33]. Nevertheless, the psychological response is not universally positive. Between 20-30% of patients report body-image concerns, especially following implant-based reconstruction. Sexual well-being may also be negatively affected in some cases. These concerns highlight the importance of individualized counseling before surgery and the need for realistic expectations about postoperative appearance and function [34].

Surgical complication rates vary between 9% and 20%, with higher rates in autologous flap reconstructions due to increased procedural complexity. Although these complications rarely offset the oncologic benefits, they influence recovery time, physical comfort, and long-term satisfaction. Thus, while BPM confers unparalleled cancer risk reduction, the procedure must be weighed against the physical and emotional consequences that accompany any major surgery. Table (6) shows the included subjects about Psychosocial and Surgical Outcomes: Balancing Benefit and Burden.

Table 6. The included subjects about Psychosocial and Surgical Outcomes: Balancing Benefit and Burden

Heterogeneity in Evidence and Robustness of Findings

The strength of evidence supporting BPM, although considerable, is tempered by study heterogeneity. Table 3 illustrates this variability through heterogeneity and sensitivity analyses. The overall heterogeneity (I²=62%) indicates moderate variability across studies, likely due to differences in:

ü  follow-up duration.

ü  reconstruction techniques.

ü  sample sizes.

ü  study designs (prospective vs. retrospective) [35].

ü  population characteristics.

ü  Mutation type distribution.

Despite this, sensitivity analyses consistently show that the effect of BPM on breast cancer incidence remains stable regardless of which study is removed from the dataset. Subgroup analyses demonstrate that BRCA1 and BRCA2 carriers both benefit substantially; however, heterogeneity decreases markedly when low-quality and small-sample studies are removed [36].

Prospective studies show lower heterogeneity (30%) compared with retrospective studies (66%), reinforcing the need for more prospective long-term data. Notably, exclusion of two outlier studies reduced heterogeneity to 22%, strengthening the pooled risk estimate (RR=0.05). Thus, although heterogeneity exists, the consistency of effect size indicates high methodological robustness. Table (7) illustrates the included subjects about Heterogeneity in Evidence and Robustness of Findings.

Table 7. The included subjects about Heterogeneity in Evidence and Robustness of Findings